TYRA - NASDAQ
Tyra Biosciences, Inc.
$26.60
-7.3%Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
At a Glance
Live Snapshottyra
Other Non-Current Assets
Last Annual Value
10.27M
3-Year CAGR
24%
5-Year CAGR
245%
10-Year CAGR
55%
Tyra Biosciences, Inc. Competitors Analysis of Other Non-Current Assets
| Company | Other Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Tyra Biosciences, Inc. NASDAQ:TYRA | 10.27M | 19.4% | 79.3% | N/A | |
 Savara Inc. NASDAQ:SVRA | 84.00K | -39.9% | -19.7% | -4.3% | |
 ProKidney Corp. NASDAQ:PROK | 0.00 | N/A | N/A | N/A | |
 Kura Oncology, Inc. NASDAQ:KURA | 14.54M | 24.1% | 32.8% | 31.1% | |
 Prime Medicine, Inc. NASDAQ:PRME | 14.69M | 1.0% | -1.2% | N/A | |
 Rezolute, Inc. NASDAQ:RZLT | 2.92M | 170.4% | 72.6% | 22.8% | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 192.14M | 174.2% | 113.3% | N/A | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 15.12M | 365.4% | 151.6% | 49.9% | |
 Geron Corporation NASDAQ:GERN | 8.10M | 19.9% | 11.0% | N/A | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 230.00K | 2.4% | 6.4% | N/A |
Tyra Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your TYRA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.